

Tara Gomes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3098299/publications.pdf>

Version: 2024-02-01

281
papers

10,533
citations

46918

47
h-index

40881

93
g-index

287
all docs

287
docs citations

287
times ranked

12211
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada. <i>Pain</i> , 2022, 163, e129-e136.	2.0	3
2	Trends in Hospitalizations for Serious Infections Among People With Opioid Use Disorder in Ontario, Canada. <i>Journal of Addiction Medicine</i> , 2022, 16, 433-439.	1.4	16
3	Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study. <i>European Urology Focus</i> , 2022, 8, 1433-1440.	1.6	5
4	The effects of COVID-19 on the dispensing rates of antidepressants and benzodiazepines in Canada. <i>Depression and Anxiety</i> , 2022, 39, 156-162.	2.0	14
5	Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion. <i>JAMA Network Open</i> , 2022, 5, e2143050.	2.8	1
6	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	1.3	0
7	Comparisons of Insulin Spending and Price Between Canada and the United States. <i>Mayo Clinic Proceedings</i> , 2022, 97, 573-578.	1.4	2
8	Perioperative opioid-prescribing practices of resident trainees compared with staff surgeons. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 859-860.e2.	0.7	2
9	Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. <i>International Journal of Drug Policy</i> , 2022, 102, 103601.	1.6	22
10	Interprovincial variation in antibiotic use in Canada, 2019: a retrospective cross-sectional study. <i>CMAJ Open</i> , 2022, 10, E262-E268.	1.1	2
11	Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 846.	3.8	43
12	Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study. <i>Addiction</i> , 2022, 117, 1972-1981.	1.7	9
13	Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors. <i>Canadian Journal of Hospital Pharmacy</i> , 2022, 75, 104-107.	0.1	1
14	Addressing the overdose crisis in North America with bold action. <i>Addiction</i> , 2022, 117, 1194-1196.	1.7	8
15	Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis. <i>International Journal of Drug Policy</i> , 2022, 103, 103644.	1.6	17
16	Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study. <i>Thrombosis Research</i> , 2022, 213, 57-64.	0.8	2
17	Opioid prescribing practices in chronic kidney disease: a population-based cohort study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2408-2417.	0.4	1
18	Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study. <i>Canada Communicable Disease Report</i> , 2022, 48, 170-178.	0.6	1

#	ARTICLE	IF	CITATIONS
19	The Risk of Ventricular Dysrhythmia or Sudden Death in Patients Receiving Serotonin Reuptake Inhibitors With Methadone: A Population-Based Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 861953.	1.6	1
20	Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data. <i>Cmaj</i> , 2022, 194, E556-E560.	0.9	5
21	Identifying the changing age distribution of opioid-related mortality with high-frequency data. <i>PLoS ONE</i> , 2022, 17, e0265509.	1.1	1
22	Impact of acetaminophen product labelling changes in Canada on hospital admissions for accidental acetaminophen overdose: a population-based study. <i>Cmaj</i> , 2022, 194, E542-E548.	0.9	7
23	Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: a population-based time series analysis. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109459.	1.6	6
24	Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. <i>International Journal of Drug Policy</i> , 2022, 104, 103680.	1.6	6
25	Evaluating the population-level effects of oxycodone restrictions on prescription opioid utilization in Ontario. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	0.9	1
26	International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID-19 pandemic: A cross-sectional analysis of 66 countries. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 779-787.	0.9	5
27	Risk of suicide death following electroconvulsive therapy treatment for depression: a propensity score-weighted, retrospective cohort study in Canada. <i>Lancet Psychiatry</i> , 2022, 9, 435-446.	3.7	16
28	Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109473.	1.6	3
29	Categorization of Opioid Use Among Pregnant People and Association With Overdose or Death. <i>JAMA Network Open</i> , 2022, 5, e2214688.	2.8	5
30	Association of obstructive sleep apnea and opioids use on adverse health outcomes: A population study of health administrative data. <i>PLoS ONE</i> , 2022, 17, e0269112.	1.1	3
31	Metronidazole-associated Neurologic Events: A Nested Case-control Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 2095-2100.	2.9	21
32	Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015-2018). <i>Canadian Journal of Public Health</i> , 2021, 112, 89-96.	1.1	11
33	Patient-level Characteristics and Inequitable Access to Inpatient Electroconvulsive Therapy for Depression: A Population-based Cross-sectional Study: Caractéristiques au niveau du patient et accès inéquitable à la thérapie électroconvulsive pour patients hospitalisés. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 147-158.	0.9	13
34	Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 279-284.	2.9	8
35	Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis. <i>Addiction</i> , 2021, 116, 1514-1520.	1.7	11
36	Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 950-960.	2.2	12

#	ARTICLE	IF	CITATIONS
37	Initial opioid prescription patterns and the risk of ongoing use and adverse outcomes. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 379-389.	0.9	12
38	Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 739-745.	2.3	16
39	Medication use and its impact on high-cost health care users among older adults: protocol for the population-based matched cohort HiCOSTT study. <i>CMAJ Open</i> , 2021, 9, E44-E52.	1.1	2
40	Prevalence of Prenatal Opioid Exposure in Ontario, Canada, 2014-2019. <i>JAMA Network Open</i> , 2021, 4, e2037388.	2.8	14
41	Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. <i>Journal of General Internal Medicine</i> , 2021, 36, 2601-2607.	1.3	9
42	Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada. <i>Canadian Liver Journal</i> , 2021, 4, 426-429.	0.3	4
43	Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. <i>Cmaj</i> , 2021, 193, E304-E309.	0.9	13
44	A qualitative study of a publicly funded pharmacy-dispensed naloxone program. <i>International Journal of Drug Policy</i> , 2021, 92, 103146.	1.6	16
45	Choppy waters: The importance of accounting for shifting drug utilization during the COVID-19 pandemic in future observational drug-related studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 649-651.	1.2	4
46	Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada. <i>Canadian Liver Journal</i> , 2021, 4, 51-58.	0.3	5
47	Cohort profile: development and characteristics of a retrospective cohort of individuals dispensed prescription opioids for non-cancer pain in British Columbia, Canada. <i>BMJ Open</i> , 2021, 11, e043586.	0.8	5
48	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 444-452.	0.5	2
49	Prescription opioid characteristics at initiation for non-cancer pain and risk of treated opioid use disorder: A population-based study. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108601.	1.6	5
50	Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada. <i>American Journal of Gastroenterology</i> , 2021, 116, 1738-1740.	0.2	4
51	Adverse event rates associated with oral anticoagulant treatment early versus later after hospital discharge in older adults: a retrospective population-based cohort study. <i>CMAJ Open</i> , 2021, 9, E364-E375.	1.1	4
52	Adherence at 2 years with distribution of essential medicines at no charge: The CLEAN Meds randomized clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003590.	3.9	9
53	Association of Opioid Consumption Profiles After Hospitalization With Risk of Adverse Health Care Events. <i>JAMA Network Open</i> , 2021, 4, e218782.	2.8	20
54	A practical overview and decision tool for analyzing recurrent events in mental illness: A review. <i>Journal of Psychiatric Research</i> , 2021, 137, 7-13.	1.5	6

#	ARTICLE	IF	CITATIONS
55	Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e2112865.	2.8	54
56	Trends in Postpartum Opioid Prescribing: A Time Series Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1004-1010.	2.3	3
57	Dental Opioid Prescription Characteristics and the Risk of New, Persistent Use. <i>American Journal of Preventive Medicine</i> , 2021, 60, 831-839.	1.6	9
58	Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003631.	3.9	4
59	Opioid Prescribing Practices for Women Undergoing Elective Gynecologic Surgery. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1325-1333.e3.	0.3	19
60	Measuring the impacts of the <i>Using Antibiotics Wisely</i> campaign on Canadian community utilization of oral antibiotics for respiratory tract infections: a time-series analysis from 2015 to 2019. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2472-2478.	1.3	7
61	Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2320-2328.	2.2	12
62	Risk of serious medical events in patients with depression treated with electroconvulsive therapy: a propensity score-matched, retrospective cohort study. <i>Lancet Psychiatry</i> , 2021, 8, 686-695.	3.7	36
63	Impact of Clinical Practice Guidelines on Blood Glucose Test Strip Prescription Rates in Manitoba and Saskatchewan (Canada): An Interrupted Time-Series Analysis. <i>Canadian Journal of Diabetes</i> , 2021, 45, 557-565.e2.	0.4	1
64	Trends and outcomes of serious complications associated with non-fatal opioid overdoses in Ontario, Canada. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108830.	1.6	9
65	Greater than the Sum: Applying Daily-Dose Equivalents to Antipsychotic Prescription Claims to Study Real-World Effects. <i>Frontiers in Pharmacology</i> , 2021, 12, 709349.	1.6	1
66	The association between prescription opioid dispensing and opioid-related morbidity and mortality in Ontario, Canada: an ecological study of public health units. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108989.	1.6	7
67	Concordance between high antibiotic prescribing and high opioid prescribing among primary care physicians: a cross-sectional study. <i>CMAJ Open</i> , 2021, 9, E175-E180.	1.1	1
68	Identification of Prenatal Opioid Exposure Within Health Administrative Databases. <i>Pediatrics</i> , 2021, 147, .	1.0	7
69	Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults. <i>JAMA Network Open</i> , 2021, 4, e2130795.	2.8	17
70	Comparison of claims from high-drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis. <i>CMAJ Open</i> , 2021, 9, E1048-E1054.	1.1	0
71	Language proficiency and warfarin-related adverse events in older immigrants and Canadian residents: a population-based cohort study. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 590-598.	0.3	1
72	New Opioid Use and Risk of Emergency Department Visits Related to Motor Vehicle Collisions in Ontario, Canada. <i>JAMA Network Open</i> , 2021, 4, e2134248.	2.8	3

#	ARTICLE	IF	CITATIONS
73	Prescription opioid treatment for non-cancer pain and initiation of injection drug use: large retrospective cohort study. <i>BMJ, The</i> , 2021, 375, e066965.	3.0	15
74	Validation of self-reported opioid agonist treatment among people who inject drugs using prescription dispensation records. <i>Epidemiology</i> , 2021, Publish Ahead of Print, .	1.2	3
75	The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis. <i>CMAJ Open</i> , 2021, 9, E1181-E1186.	1.1	1
76	Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis. <i>CMAJ Open</i> , 2021, 9, E1055-E1062.	1.1	5
77	Extent of a valsartan drug shortage and its effect on antihypertensive drug use in the Canadian population: a national cross-sectional study. <i>CMAJ Open</i> , 2021, 9, E1128-E1133.	1.1	10
78	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 444-452.	0.5	1
79	Effect on Treatment Adherence of Distributing Essential Medicines at No Charge. <i>JAMA Internal Medicine</i> , 2020, 180, 27.	2.6	41
80	Trends in opioid use before critical illness among elderly patients in Ontario. <i>Journal of Critical Care</i> , 2020, 55, 128-133.	1.0	1
81	Comprehensive Drug-Class Review Framework for improved evidence-based drug policy and formulary modernization. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 12-19.	0.2	5
82	Assessing the impact of an opioid prescribing guideline for dentists in Ontario, Canada. <i>Journal of the American Dental Association</i> , 2020, 151, 43-50.	0.7	6
83	One-Year Mortality After Emergency Department Visit for Nonfatal Opioid Poisoning: A Population-Based Analysis. <i>Annals of Emergency Medicine</i> , 2020, 75, 20-28.	0.3	19
84	Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. <i>Value in Health</i> , 2020, 23, 1137-1141.	0.1	14
85	Fall-Related Hospitalizations in Nursing Home Residents Co-Prescribed a Cholinesterase Inhibitor and Beta-Blocker. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2516-2524.	1.3	3
86	Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108238.	1.6	9
87	New Opioid Use after Invasive Mechanical Ventilation and Hospital Discharge. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 568-575.	2.5	34
88	Effect of Academic Detailing on Promoting Appropriate Prescribing of Antipsychotic Medication in Nursing Homes. <i>JAMA Network Open</i> , 2020, 3, e205724.	2.8	12
89	The Role of the Medical School Training on Physician Opioid Prescribing Practices: Evidence from Ontario, Canada: Le rôle de la formation à la faculté de médecine à l'égard des pratiques de prescription d'opioïdes des médecins: données probantes d'Ontario, Canada. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 710-720.	0.9	2
90	Opioid use and initiation of positive airway pressure treatment in adults referred for sleep disorder assessment: An explanatory population-based study. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 194-204.	0.2	2

#	ARTICLE	IF	CITATIONS
91	Evaluation of opioid discontinuation after non-orthopaedic surgery among chronic opioid users: a population-based cohort study. <i>British Journal of Anaesthesia</i> , 2020, 124, 281-291.	1.5	14
92	Oxycodone, Hydromorphone, and the Risk of Suicide: A Retrospective Population-Based Caseâ€“Control Study. <i>Drug Safety</i> , 2020, 43, 737-743.	1.4	3
93	Characteristics of highâ€“drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis. <i>CMAJ Open</i> , 2020, 8, E297-E303.	1.1	3
94	Evaluating the intended and unintended consequences of opioid-prescribing interventions on primary care in British Columbia, Canada: protocol for a retrospective population-based cohort study. <i>BMJ Open</i> , 2020, 10, e038724.	0.8	3
95	Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015. <i>Canadian Journal of Diabetes</i> , 2019, 43, 179-185.e1.	0.4	11
96	Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. <i>Thrombosis Research</i> , 2019, 182, 12-19.	0.8	10
97	Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Olderâ€“A Population-Based Cohort Study. <i>JAMA Internal Medicine</i> , 2019, 179, 1436.	2.6	6
98	The uptake of the pharmacy-dispensed naloxone kit program in Ontario: A population-based study. <i>PLoS ONE</i> , 2019, 14, e0223589.	1.1	27
99	Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. <i>JAMA Network Open</i> , 2019, 2, e1913304.	2.8	19
100	Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study. <i>CMAJ Open</i> , 2019, 7, E582-E589.	1.1	14
101	â€œLike being put on an ice floe and shoved awayâ€“ A qualitative study of the impacts of opioid-related policy changes on people who take opioids. <i>International Journal of Drug Policy</i> , 2019, 66, 15-22.	1.6	63
102	Tramadol and the risk of seizure: nested case-control study of US patients with employer-sponsored health benefits. <i>BMJ Open</i> , 2019, 9, e026705.	0.8	16
103	Impact of delisting highâ€“strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 726-733.	0.9	14
104	Evaluation of the fentanyl patch-for-patch program in Ontario, Canada. <i>International Journal of Drug Policy</i> , 2019, 66, 82-86.	1.6	8
105	Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study. <i>BMJ Open</i> , 2019, 9, e028125.	0.8	10
106	Incremental healthcare utilisation and costs among new senior high-cost users in Ontario, Canada: a retrospective matched cohort study. <i>BMJ Open</i> , 2019, 9, e028637.	0.8	6
107	Unplanned index hospital admissions among new older high-cost health care users in Ontario: a population-based matched cohort study. <i>CMAJ Open</i> , 2019, 7, E537-E545.	1.1	6
108	Understanding the Implications of a Shifting Opioid Landscape in Ontario. <i>Healthcare Quarterly (Toronto, Ont)</i> , 2019, 22, 6-11.	0.3	16

#	ARTICLE	IF	CITATIONS
109	Rates of Infective Endocarditis in Substance Use Disorder and Associated Costs in Ontario. <i>Canadian Journal of Addiction</i> , 2019, 10, 36-43.	0.2	10
110	Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage. <i>JAMA Network Open</i> , 2019, 2, e1917053.	2.8	15
111	Do Diagnostic and Procedure Codes Within Population-Based, Administrative Datasets Accurately Identify Patients with Rectal Cancer?. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 367-376.	0.9	0
112	Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario. <i>Addiction</i> , 2019, 114, 268-277.	1.7	5
113	Quality of primary care among individuals receiving treatment for opioid use disorder. <i>Canadian Family Physician</i> , 2019, 65, 343-351.	0.1	18
114	Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada. <i>Neurourology and Urodynamics</i> , 2018, 37, 1693-1700.	0.8	3
115	Trends and uptake of new formulations of controlled-release oxycodone in Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 520-525.	0.9	6
116	Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program. <i>CMAJ Open</i> , 2018, 6, E132-E138.	1.1	4
117	Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 419-429.	3.1	45
118	Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 361-369.	0.9	56
119	Opioid Use After ICU Admission Among Elderly Chronic Opioid Users in Ontario: A Population-Based Cohort Study. <i>Critical Care Medicine</i> , 2018, 46, 1934-1942.	0.4	13
120	Measuring the Burden of Opioid-related Mortality in Ontario, Canada. <i>Journal of Addiction Medicine</i> , 2018, 12, 418-419.	1.4	43
121	Regional variation in healthcare spending and mortality among senior high-cost healthcare users in Ontario, Canada: a retrospective matched cohort study. <i>BMC Geriatrics</i> , 2018, 18, 262.	1.1	14
122	Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults. <i>Canadian Geriatrics Journal</i> , 2018, 21, 269-273.	0.7	13
123	Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study. <i>Cmaj</i> , 2018, 190, E1376-E1383.	0.9	21
124	Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. <i>BMJ: British Medical Journal</i> , 2018, 362, k3207.	2.4	103
125	Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study. <i>Pain</i> , 2018, 159, 1562-1568.	2.0	60
126	Association between perioperative beta blocker use and cancer survival following surgical resection. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1164-1169.	0.5	31

#	ARTICLE	IF	CITATIONS
127	The Burden of Opioid-Related Mortality in the United States. <i>JAMA Network Open</i> , 2018, 1, e180217.	2.8	484
128	A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 160.	0.8	4
129	Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 464-468.	0.5	2
130	Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: A multi-jurisdictional cross-sectional study. <i>Drug and Alcohol Dependence</i> , 2018, 191, 86-90.	1.6	24
131	Second-generation anti-depressants and risk of new-onset seizures in the elderly. <i>Clinical Toxicology</i> , 2018, 56, 1179-1184.	0.8	7
132	Opioid prescribing and adverse events in opioid-naïve patients treated by emergency physicians versus family physicians: a population-based cohort study. <i>CMAJ Open</i> , 2018, 6, E110-E117.	1.1	14
133	Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA/LABA combination products: A population-based study. <i>Respiratory Medicine</i> , 2018, 143, 1-7.	1.3	5
134	Pregabalin and the Risk for Opioid-Related Death: A Nested Case-€“Control Study. <i>Annals of Internal Medicine</i> , 2018, 169, 732.	2.0	116
135	Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. <i>PLoS Medicine</i> , 2018, 15, e1002584.	3.9	82
136	Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies. <i>Lancet Psychiatry</i> , 2018, 5, 644-652.	3.7	83
137	Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 59-65.e2.	0.5	18
138	Evaluation of Definitions for Oral Anticoagulant-€“Associated Major Bleeding: A Population-Based Cohort Study. <i>Blood</i> , 2018, 132, 426-426.	0.6	3
139	Evaluating the early impacts of delisting high-strength opioids on patterns of prescribing in Ontario. <i>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</i> , 2018, 38, 256-262.	0.8	10
140	Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada. <i>Canadian Journal of Diabetes</i> , 2017, 41, 138-142.	0.4	3
141	Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding. <i>Chest</i> , 2017, 152, 81-91.	0.4	68
142	Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1544.	3.8	114
143	Lipophilic ð-Blockers and Suicide in the Elderly. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 381-384.	0.7	4
144	Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study. <i>Drug Safety</i> , 2017, 40, 835-840.	1.4	9

#	ARTICLE	IF	CITATIONS
145	Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. <i>Cmaj</i> , 2017, 189, E4-E10.	0.9	41
146	Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully selected and Easily Accessible at No Charge Medicines (CLEAN Meds) trial. <i>BMJ Open</i> , 2017, 7, e015686.	0.8	7
147	Pregabalin and heart failure: <scp>A</scp> population-based study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1087-1092.	0.9	13
148	More Rigorous Study Needed Before Claiming No Harm of Blood Glucose Test Strip Limits for Patients Using Insulin—Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 890.	2.6	0
149	Impact of Unrestricted Access to Pregabalin on the Use of Opioids and Other CNS-Active Medications: A Cross-Sectional Time Series Analysis. <i>Pain Medicine</i> , 2017, 18, 1019-1026.	0.9	28
150	Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014. <i>Drug and Alcohol Dependence</i> , 2017, 177, 315-321.	1.6	18
151	Prenatal Antidepressant Use and Autism Spectrum Disorder—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 665.	3.8	2
152	Prevalence and characteristics of opioid-related deaths involving alcohol in Ontario, Canada. <i>Drug and Alcohol Dependence</i> , 2017, 179, 416-423.	1.6	18
153	Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes. <i>JAMA Internal Medicine</i> , 2017, 177, 61.	2.6	15
154	The appropriateness and persistence of testosterone replacement therapy in Ontario. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 119-126.	0.9	7
155	Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis. <i>CMAJ Open</i> , 2017, 5, E800-E807.	1.1	25
156	Senior high-cost healthcare users—resource utilization and outcomes: a protocol of a retrospective matched cohort study in Canada. <i>BMJ Open</i> , 2017, 7, e018488.	0.8	6
157	Availability of naloxone in Canadian pharmacies: a population-based survey. <i>CMAJ Open</i> , 2017, 5, E779-E784.	1.1	20
158	Impact of a Graduated Approach on Opioid Initiation and Loss of Earnings Following Workplace Injury. <i>Journal of Occupational and Environmental Medicine</i> , 2017, 59, 1197-1201.	0.9	1
159	Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study. <i>Canadian Urological Association Journal</i> , 2017, 12, E142-5.	0.3	5
160	Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case—control study. <i>PLoS Medicine</i> , 2017, 14, e1002396.	3.9	362
161	Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants. <i>Healthcare Policy</i> , 2017, 13, 68-78.	0.3	2
162	First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. <i>Canadian Family Physician</i> , 2017, 63, e277-e283.	0.1	8

#	ARTICLE	IF	CITATIONS
163	Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study. <i>CMAJ Open</i> , 2016, 4, E292-E297.	1.1	7
164	The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-7.	0.8	4
165	High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study. <i>PLoS ONE</i> , 2016, 11, e0167479.	1.1	43
166	The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial Fibrillation. <i>PLoS ONE</i> , 2016, 11, e0149142.	1.1	29
167	Off-label use of inhaled tobramycin in Ontario, Canada. <i>Thorax</i> , 2016, 71, 862-864.	2.7	1
168	Opioid Use and Overdose: What We've Learned in Ontario. <i>Healthcare Quarterly</i> , 2016, 18, 8-11.	0.7	23
169	Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 803-807.	0.7	0
170	Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study. <i>Drugs - Real World Outcomes</i> , 2016, 3, 175-182.	0.7	12
171	Self-Monitoring of Blood Glucose Levels: Evaluating the Impact of a Policy of Quantity Limits on Test-Strip Use and Costs. <i>Canadian Journal of Diabetes</i> , 2016, 40, 431-435.	0.4	11
172	Interprovincial Variation in Antipsychotic and Antidepressant Prescriptions Dispensed in the Canadian Pediatric Population. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 758-765.	0.9	20
173	Sensitivity and specificity of administrative mortality data for identifying prescription opioid-related deaths. <i>Cmaj</i> , 2016, 188, E67-E72.	0.9	19
174	Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study. <i>Canadian Journal of Cardiology</i> , 2016, 32, 986.e17-986.e22.	0.8	21
175	Antiepileptic use for epilepsy and nonepilepsy disorders. <i>Neurology</i> , 2016, 86, 939-946.	1.5	29
176	Factors that may be influencing the rise in prescription testosterone replacement therapy in adult men: a qualitative study. <i>Aging Male</i> , 2016, 19, 90-95.	0.9	11
177	Varenicline and Risk of Self-Harm: A Nested Case-Control Study. <i>PLoS ONE</i> , 2016, 11, e0163681.	1.1	1
178	Opioid prescribing is a surrogate for inadequate pain management resources. <i>Canadian Family Physician</i> , 2016, 62, 465-8.	0.1	27
179	Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada. <i>Journal of Addiction Medicine</i> , 2015, 9, 440-446.	1.4	42
180	Appropriate prescribing in nursing homes demonstration project (APDP) study protocol: pragmatic, cluster-randomized trial and mixed methods process evaluation of an Ontario policy-maker initiative to improve appropriate prescribing of antipsychotics. <i>Implementation Science</i> , 2015, 11, 45.	2.5	18

#	ARTICLE	IF	CITATIONS
181	A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 662-669.	1.1	11
182	Triptans for Acute Migraine: Drug Class Review to Help Inform Policy Decisions. <i>Headache</i> , 2015, 55, 191-198.	1.8	4
183	Trends in the coprescription of proton pump inhibitors with clopidogrel: an ecological analysis. <i>CMAJ Open</i> , 2015, 3, E428-E431.	1.1	9
184	Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. <i>Headache</i> , 2015, 55, 221-235.	1.8	197
185	Public Drug Coverage and Its Impact on Triptan Use Across Canada: A Population-Based Study. <i>Headache</i> , 2015, 55, 212-220.	1.8	4
186	Access to Triptans for Acute Episodic Migraine: A Qualitative Study. <i>Headache</i> , 2015, 55, 199-211.	1.8	8
187	Retrospective analysis of trends in dispensing long-acting non-tamper-resistant oxycodone near the Canada-United States border. <i>CMAJ Open</i> , 2015, 3, E231-E235.	1.1	4
188	The impact of policies to reduce blood glucose test strip utilization and costs in Canada. <i>Canadian Journal of Public Health</i> , 2015, 106, e210-e216.	1.1	5
189	Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 1120-1122.	1.0	9
190	Neonatal opioid withdrawal and antenatal opioid prescribing. <i>CMAJ Open</i> , 2015, 3, E55-E61.	1.1	41
191	Prescription Stimulant Use and Hospitalization for Psychosis or Mania. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 667-671.	0.7	20
192	Rates of Anomalous Bupropion Prescriptions in Ontario, Canada. <i>Annals of Family Medicine</i> , 2015, 13, 343-346.	0.9	7
193	Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. <i>Cmaj</i> , 2015, 187, 174-180.	0.9	54
194	Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. <i>Cmaj</i> , 2015, 187, E138-E143.	0.9	50
195	Safety of valproic acid in patients with chronic obstructive pulmonary disease: a population-based cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 256-261.	0.9	2
196	Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. <i>BMJ</i> , The, 2015, 350, h2298-h2298.	3.0	115
197	Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. <i>CMAJ Open</i> , 2015, 3, E166-E171.	1.1	154
198	Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study. <i>American Heart Journal</i> , 2015, 170, 133-140.e3.	1.2	28

#	ARTICLE	IF	CITATIONS
199	Predictors of Opioid-Related Death During Methadone Therapy. <i>Journal of Substance Abuse Treatment</i> , 2015, 57, 30-35.	1.5	52
200	Sex Differences in Dose Escalation and Overdose Death during Chronic Opioid Therapy: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0134550.	1.1	124
201	The Impact of Drug Reimbursement Policy on Rates of Testosterone Replacement Therapy among Older Men. <i>PLoS ONE</i> , 2014, 9, e98003.	1.1	28
202	Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. <i>BMJ, The</i> , 2014, 349, g6196-g6196.	3.0	84
203	Reply to Strandberg and Tienari. <i>Clinical Infectious Diseases</i> , 2014, 58, 1043-1044.	2.9	1
204	Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study. <i>PLoS Medicine</i> , 2014, 11, e1001736.	3.9	60
205	Extended-release nifedipine and the risk of intestinal obstruction: a population-based study. <i>BMJ Open</i> , 2014, 4, e005377-e005377.	0.8	4
206	The Ontario Drug Policy Research Network: Bridging the gap between Research and Drug Policy. <i>Health Policy</i> , 2014, 117, 392-398.	1.4	15
207	Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysis. <i>CMAJ Open</i> , 2014, 2, E256-E261.	1.1	62
208	Impact of the JUPITER Trial on Statin Prescribing for Primary Prevention. <i>Pharmacotherapy</i> , 2014, 34, 9-18.	1.2	5
209	Upper Gastrointestinal Bleeding in Elderly Adults with Dementia Receiving Cholinesterase Inhibitors: A Population-Based Cohort Study. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 382-384.	1.3	10
210	The burden of premature opioid-related mortality. <i>Addiction</i> , 2014, 109, 1482-1488.	1.7	125
211	Risk of overdose and death following codeine prescription among immigrants. <i>Journal of Epidemiology and Community Health</i> , 2014, 68, 1057-1063.	2.0	7
212	Statins and the Risk of Herpes Zoster: A Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 350-356.	2.9	45
213	Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study. <i>BMC Nephrology</i> , 2014, 15, 79.	0.8	13
214	Altered mental status in older adults with histamine2-receptor antagonists: A population-based study. <i>European Journal of Internal Medicine</i> , 2014, 25, 701-709.	1.0	17
215	Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2483-2488.	3.1	20
216	Temporal Trend of Carpal Tunnel Release Surgery: A Population-Based Time Series Analysis. <i>PLoS ONE</i> , 2014, 9, e97499.	1.1	21

#	ARTICLE	IF	CITATIONS
217	Adverse Cardiac Events in Older Patients Receiving Venlafaxine. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e552-e558.	1.1	23
218	Trends in high-dose opioid prescribing in Canada. <i>Canadian Family Physician</i> , 2014, 60, 826-32.	0.1	85
219	Statin Toxicity From Macrolide Antibiotic Coprescription. <i>Annals of Internal Medicine</i> , 2013, 158, 869.	2.0	132
220	Hospitalization for Hemorrhage Among Warfarin Recipients Prescribed Amiodarone. <i>American Journal of Cardiology</i> , 2013, 112, 420-423.	0.7	23
221	Risk of Acute Kidney Injury From Oral Acyclovir: A Population-Based Study. <i>American Journal of Kidney Diseases</i> , 2013, 61, 723-729.	2.1	42
222	No Increase in Adverse Events During Aliskiren Use Among Ontario Patients Receiving Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers. <i>Canadian Journal of Cardiology</i> , 2013, 29, 586-591.	0.8	14
223	Progression through diabetes therapies among new elderly users of metformin: a population-based study. <i>Diabetic Medicine</i> , 2013, 30, e51-e55.	1.2	5
224	Risk of incident diabetes among patients treated with statins: population based study. <i>BMJ, The</i> , 2013, 346, f2610-f2610.	3.0	338
225	Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. <i>Cmaj</i> , 2013, 185, 1035-1041.	0.9	18
226	Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions. <i>BMJ Open</i> , 2013, 3, e002857.	0.8	20
227	Rates of hemorrhage during warfarin therapy for atrial fibrillation. <i>Cmaj</i> , 2013, 185, E121-E127.	0.9	159
228	Trends in selection and timing of first-line pharmacotherapy in older patients with Type 2 diabetes diagnosed between 1994 and 2006. <i>Diabetic Medicine</i> , 2013, 30, 1209-1213.	1.2	15
229	Opioid Dose and Risk of Road Trauma in Canada. <i>JAMA Internal Medicine</i> , 2013, 173, 196.	2.6	127
230	Chlorthalidone Versus Hydrochlorothiazide for the Treatment of Hypertension in Older Adults. <i>Annals of Internal Medicine</i> , 2013, 158, 447.	2.0	88
231	Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: A retrospective cohort study. <i>Clinical Toxicology</i> , 2012, 50, 390-395.	0.8	30
232	The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly. <i>Archives of Internal Medicine</i> , 2012, 172, 1739.	4.3	159
233	Persistence With Therapy Among Patients Treated With Warfarin for Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2012, 172, 1687.	4.3	69
234	Oral bisphosphonate use in the elderly is not associated with acute kidney injury. <i>Kidney International</i> , 2012, 82, 903-908.	2.6	46

#	ARTICLE	IF	CITATIONS
235	Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1591-1598.	0.4	23
236	Long-term Analgesic Use: Sometimes Less Is Not More—Reply. <i>Archives of Internal Medicine</i> , 2012, 172, 1189.	4.3	3
237	Antidepressants, metoprolol and the risk of bradycardia. <i>Therapeutic Advances in Psychopharmacology</i> , 2012, 2, 43-49.	1.2	12
238	Effects of Funding Policy Changes and Health Warnings on the Use of Erythropoiesis-Stimulating Agents. <i>Journal of Oncology Practice</i> , 2012, 8, 179-183.	2.5	10
239	Long-term Analgesic Use After Low-Risk Surgery. <i>Archives of Internal Medicine</i> , 2012, 172, 425.	4.3	669
240	Inviting Patients to Read Doctors' Notes. <i>Annals of Internal Medicine</i> , 2012, 156, 608.	2.0	50
241	Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers and Cardiovascular Outcomes in Chronic Dialysis Patients: A Population-Based Cohort Study. <i>Archives of Internal Medicine</i> , 2012, 172, 591-3.	4.3	15
242	Selective Serotonin Reuptake Inhibitors and Pulmonary Arterial Hypertension. <i>Chest</i> , 2012, 141, 348-353.	0.4	16
243	A Population-Based Assessment of the Drug Interaction Between Levothyroxine and Warfarin. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 766-770.	2.3	17
244	Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. <i>Diabetic Medicine</i> , 2012, 29, 1524-1528.	1.2	22
245	Antidepressant use, serotonin transporter affinity, and reinfarction among patients receiving clopidogrel: a population-based study. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1328-1333.	0.9	1
246	The impact of federal warnings on publically funded desmopressin utilization among children in Ontario. <i>Journal of Pediatric Urology</i> , 2012, 8, 249-253.	0.6	8
247	Comparative adherence to oxybutynin or tolterodine among older patients. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1121-1121.	0.8	13
248	Use of other opioids during methadone therapy: a population-based study. <i>Addiction</i> , 2012, 107, 776-780.	1.7	23
249	Comparative adherence to oxybutynin or tolterodine among older patients. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 97-99.	0.8	28
250	Reformulation of controlled-release oxycodone and pharmacy dispensing patterns near the US-Canada border. <i>Open Medicine</i> , 2012, 6, e141-5.	1.5	4
251	Relationship of asthma management, socioeconomic status, and medication insurance characteristics to exacerbation frequency in children with asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 106, 17-23.	0.5	68
252	Risk of Serious Falls Associated With Oxybutynin and Tolterodine: A Population Based Study. <i>Journal of Urology</i> , 2011, 186, 1340-1344.	0.2	36

#	ARTICLE	IF	CITATIONS
253	Geographical Variation in Opioid Prescribing and Opioid-Related Mortality in Ontario. <i>Healthcare Quarterly</i> , 2011, 14, 22-24.	0.7	62
254	Orlistat and Acute Kidney Injury: An Analysis of 953 Patients. <i>Archives of Internal Medicine</i> , 2011, 171, 702.	4.3	60
255	Trimethoprim/sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 544-549.	1.1	26
256	Sevelamer Prescriptions After Reporting of the Dialysis Clinical Outcomes Revisited (DCOR) Trial Findings: An Analysis of 5,495 Patients Receiving Maintenance Dialysis in Ontario, Canada. <i>American Journal of Kidney Diseases</i> , 2011, 57, 357-359.	2.1	3
257	Hospital Admissions for Hyperkalemia With Trimethoprim-Sulfamethoxazole: A Cohort Study Using Health Care Database Codes for 393,039 Older Women With Urinary Tract Infections. <i>American Journal of Kidney Diseases</i> , 2011, 57, 521-523.	2.1	12
258	Ciprofloxacin-induced theophylline toxicity: a population-based study. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 521-526.	0.8	30
259	Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. <i>BMJ: British Medical Journal</i> , 2011, 343, d5228-d5228.	2.4	61
260	Preventing Pressure Ulcers in Long-term Care. <i>Archives of Internal Medicine</i> , 2011, 171, 1839.	4.3	56
261	Opioid Dose and Drug-Related Mortality in Patients With Nonmalignant Pain. <i>Archives of Internal Medicine</i> , 2011, 171, 686-91.	4.3	531
262	Opioids and Dose-Related Deaths—Association or Causation?—Reply. <i>Archives of Internal Medicine</i> , 2011, 171, 1687.	4.3	1
263	The Safety of Proton Pump Inhibitors and Clopidogrel in Patients After Stroke. <i>Stroke</i> , 2011, 42, 128-132.	1.0	27
264	Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1888-1894.	0.4	29
265	The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. <i>Cmaj</i> , 2011, 183, 303-307.	0.9	69
266	Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. <i>Canadian Family Physician</i> , 2011, 57, e92-6.	0.1	79
267	Trends in opioid use and dosing among socio-economically disadvantaged patients. <i>Open Medicine</i> , 2011, 5, e13-22.	1.5	67
268	Health status utilities and the impact of pressure ulcers in long-term care residents in Ontario. <i>Quality of Life Research</i> , 2010, 19, 81-89.	1.5	37
269	Trimethoprim-Sulfamethoxazole-Induced Hyperkalemia in Patients Receiving Inhibitors of the Renin-Angiotensin System. <i>Archives of Internal Medicine</i> , 2010, 170, 1045.	4.3	102
270	Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. <i>BMJ: British Medical Journal</i> , 2010, 340, c693-c693.	2.4	358

#	ARTICLE	IF	CITATIONS
271	Blood glucose test strips: options to reduce usage. Cmaj, 2010, 182, 35-38.	0.9	33
272	Cost Minimal Effectiveness of SMBG. Canadian Journal of Diabetes, 2010, 34, 180.	0.4	0
273	Beta-Blockers, Trimethoprim-Sulfamethoxazole, and the Risk of Hyperkalemia Requiring Hospitalization in the Elderly. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1544-1551.	2.2	25
274	A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Cmaj, 2009, 180, 713-718.	0.9	622
275	Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ: British Medical Journal, 2009, 339, b2942-b2942.	2.4	150
276	Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents. Pharmacoepidemiology and Drug Safety, 2009, 18, 756-760.	0.9	2
277	Macrolide-Induced Digoxin Toxicity: A Population-Based Study. Clinical Pharmacology and Therapeutics, 2009, 86, 383-386.	2.3	41
278	Toxic Megacolon in Children With Inflammatory Bowel Disease: Clinical and Radiographic Characteristics. American Journal of Gastroenterology, 2008, 103, 1524-1531.	0.2	44
279	Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia. Archives of Internal Medicine, 2008, 168, 1090.	4.3	208
280	Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes. JAMA - Journal of the American Medical Association, 2007, 298, 2634.	3.8	303
281	Variation in Nursing Home Antipsychotic Prescribing Rates. Archives of Internal Medicine, 2007, 167, 676.	4.3	155